GlassScriptPhysician profile
Douglas G Winger
NPI 1245220409
$586.91
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $36.88 · 2021: $285 · 2022: $93.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.51 | 2021 | |
| Aspira Women'S Health INC | $78.89 | 2021 | |
| Medtronic, INC. | $43.94 | 2022 | |
| Merck Sharp & Dohme LLC | $38.63 | 2019-2020 | |
| Radius Health, INC. | $29.06 | 2019 | |
| Myovant Sciences INC. | $23.90 | 2021 | |
| Therapeuticsmd, INC. | $17.32 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.66 | 2022 | |
| Shield Therapeutics INC | $13.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Winger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.